Markedly enhanced skeletal muscle transfection achieved by the ultrasound-targeted delivery of non-viral gene nanocarriers with microbubbles

Caitlin W. Burke, Jung Soo Suk, Anthony J. Kim, Yu Han J Hsiang, Alexander L. Klibanov, Justin S Hanes, Richard J. Price

Research output: Contribution to journalArticle

Abstract

Our goal was to enhance ultrasound (US)-targeted skeletal muscle transfection through the use of poly(ethyleneglycol) (PEG)/polyethylenimine (PEI) nanocomplex gene carriers and adjustments to US and microbubble (MB) parameters. C57BL/6 mice received an intravenous infusion of MBs and either naked luciferase plasmid or luciferase plasmid condensed in PEG/PEI nanocomplexes. Pulsed ultrasound (1 MHz; 0.6 MPa or 0.8 MPa) was applied to the right hindlimb for 12 min. Luciferase activity in both hindlimbs was assessed at 3, 5, 7, and 10 days post-treatment by bioluminescent imaging. When targeted to hindlimb using unsorted MBs and 0.6 MPa US, 7 days after treatment, we observed a > 60-fold increase in luciferase activity in PEG/PEI nanocomplex-treated muscles over muscles treated with naked plasmid DNA. Luciferase activity was consistently greater after treatment with PEG/PEI nanocomplexes at 0.6 MPa as compared to 0.8 MPa. The combination of small diameter MBs and 0.6 MPa US also resulted in significantly greater gene expression when compared to concentration matched intramuscular injections, a control condition in which considerably more PEG/PEI nanocomplexes were present in tissue. This result suggests that, in addition to facilitating PEG/PEI nanocomplex delivery from the bloodstream to tissue, US enhances transfection via one or more secondary mechanisms, including increased cellular uptake and/or trafficking to the nucleus of PEG/PEI nanocomplexes. We conclude that PEG/PEI nanocomplexes may be used to markedly enhance the amplitude of US-MB-targeted skeletal muscle transfection and that activating small MBs with a moderate level (0.6 MPa) of acoustic pressure can further enhance these effects.

Original languageEnglish (US)
Pages (from-to)414-421
Number of pages8
JournalJournal of Controlled Release
Volume162
Issue number2
DOIs
StatePublished - Sep 10 2012

Fingerprint

Polyethyleneimine
Microbubbles
Transfection
Skeletal Muscle
Luciferases
Genes
Hindlimb
Plasmids
Muscles
Intramuscular Injections
Inbred C57BL Mouse
Acoustics
Intravenous Infusions
Therapeutics
Gene Expression
Pressure
DNA

Keywords

  • Microbubbles
  • Nanomedicine
  • Non-viral gene delivery
  • Polyethylenimine
  • Skeletal muscle
  • Ultrasound

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Markedly enhanced skeletal muscle transfection achieved by the ultrasound-targeted delivery of non-viral gene nanocarriers with microbubbles. / Burke, Caitlin W.; Suk, Jung Soo; Kim, Anthony J.; Hsiang, Yu Han J; Klibanov, Alexander L.; Hanes, Justin S; Price, Richard J.

In: Journal of Controlled Release, Vol. 162, No. 2, 10.09.2012, p. 414-421.

Research output: Contribution to journalArticle

Burke, Caitlin W. ; Suk, Jung Soo ; Kim, Anthony J. ; Hsiang, Yu Han J ; Klibanov, Alexander L. ; Hanes, Justin S ; Price, Richard J. / Markedly enhanced skeletal muscle transfection achieved by the ultrasound-targeted delivery of non-viral gene nanocarriers with microbubbles. In: Journal of Controlled Release. 2012 ; Vol. 162, No. 2. pp. 414-421.
@article{2234dd4b886c48839d0374efdd2278dd,
title = "Markedly enhanced skeletal muscle transfection achieved by the ultrasound-targeted delivery of non-viral gene nanocarriers with microbubbles",
abstract = "Our goal was to enhance ultrasound (US)-targeted skeletal muscle transfection through the use of poly(ethyleneglycol) (PEG)/polyethylenimine (PEI) nanocomplex gene carriers and adjustments to US and microbubble (MB) parameters. C57BL/6 mice received an intravenous infusion of MBs and either naked luciferase plasmid or luciferase plasmid condensed in PEG/PEI nanocomplexes. Pulsed ultrasound (1 MHz; 0.6 MPa or 0.8 MPa) was applied to the right hindlimb for 12 min. Luciferase activity in both hindlimbs was assessed at 3, 5, 7, and 10 days post-treatment by bioluminescent imaging. When targeted to hindlimb using unsorted MBs and 0.6 MPa US, 7 days after treatment, we observed a > 60-fold increase in luciferase activity in PEG/PEI nanocomplex-treated muscles over muscles treated with naked plasmid DNA. Luciferase activity was consistently greater after treatment with PEG/PEI nanocomplexes at 0.6 MPa as compared to 0.8 MPa. The combination of small diameter MBs and 0.6 MPa US also resulted in significantly greater gene expression when compared to concentration matched intramuscular injections, a control condition in which considerably more PEG/PEI nanocomplexes were present in tissue. This result suggests that, in addition to facilitating PEG/PEI nanocomplex delivery from the bloodstream to tissue, US enhances transfection via one or more secondary mechanisms, including increased cellular uptake and/or trafficking to the nucleus of PEG/PEI nanocomplexes. We conclude that PEG/PEI nanocomplexes may be used to markedly enhance the amplitude of US-MB-targeted skeletal muscle transfection and that activating small MBs with a moderate level (0.6 MPa) of acoustic pressure can further enhance these effects.",
keywords = "Microbubbles, Nanomedicine, Non-viral gene delivery, Polyethylenimine, Skeletal muscle, Ultrasound",
author = "Burke, {Caitlin W.} and Suk, {Jung Soo} and Kim, {Anthony J.} and Hsiang, {Yu Han J} and Klibanov, {Alexander L.} and Hanes, {Justin S} and Price, {Richard J.}",
year = "2012",
month = "9",
day = "10",
doi = "10.1016/j.jconrel.2012.07.005",
language = "English (US)",
volume = "162",
pages = "414--421",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Markedly enhanced skeletal muscle transfection achieved by the ultrasound-targeted delivery of non-viral gene nanocarriers with microbubbles

AU - Burke, Caitlin W.

AU - Suk, Jung Soo

AU - Kim, Anthony J.

AU - Hsiang, Yu Han J

AU - Klibanov, Alexander L.

AU - Hanes, Justin S

AU - Price, Richard J.

PY - 2012/9/10

Y1 - 2012/9/10

N2 - Our goal was to enhance ultrasound (US)-targeted skeletal muscle transfection through the use of poly(ethyleneglycol) (PEG)/polyethylenimine (PEI) nanocomplex gene carriers and adjustments to US and microbubble (MB) parameters. C57BL/6 mice received an intravenous infusion of MBs and either naked luciferase plasmid or luciferase plasmid condensed in PEG/PEI nanocomplexes. Pulsed ultrasound (1 MHz; 0.6 MPa or 0.8 MPa) was applied to the right hindlimb for 12 min. Luciferase activity in both hindlimbs was assessed at 3, 5, 7, and 10 days post-treatment by bioluminescent imaging. When targeted to hindlimb using unsorted MBs and 0.6 MPa US, 7 days after treatment, we observed a > 60-fold increase in luciferase activity in PEG/PEI nanocomplex-treated muscles over muscles treated with naked plasmid DNA. Luciferase activity was consistently greater after treatment with PEG/PEI nanocomplexes at 0.6 MPa as compared to 0.8 MPa. The combination of small diameter MBs and 0.6 MPa US also resulted in significantly greater gene expression when compared to concentration matched intramuscular injections, a control condition in which considerably more PEG/PEI nanocomplexes were present in tissue. This result suggests that, in addition to facilitating PEG/PEI nanocomplex delivery from the bloodstream to tissue, US enhances transfection via one or more secondary mechanisms, including increased cellular uptake and/or trafficking to the nucleus of PEG/PEI nanocomplexes. We conclude that PEG/PEI nanocomplexes may be used to markedly enhance the amplitude of US-MB-targeted skeletal muscle transfection and that activating small MBs with a moderate level (0.6 MPa) of acoustic pressure can further enhance these effects.

AB - Our goal was to enhance ultrasound (US)-targeted skeletal muscle transfection through the use of poly(ethyleneglycol) (PEG)/polyethylenimine (PEI) nanocomplex gene carriers and adjustments to US and microbubble (MB) parameters. C57BL/6 mice received an intravenous infusion of MBs and either naked luciferase plasmid or luciferase plasmid condensed in PEG/PEI nanocomplexes. Pulsed ultrasound (1 MHz; 0.6 MPa or 0.8 MPa) was applied to the right hindlimb for 12 min. Luciferase activity in both hindlimbs was assessed at 3, 5, 7, and 10 days post-treatment by bioluminescent imaging. When targeted to hindlimb using unsorted MBs and 0.6 MPa US, 7 days after treatment, we observed a > 60-fold increase in luciferase activity in PEG/PEI nanocomplex-treated muscles over muscles treated with naked plasmid DNA. Luciferase activity was consistently greater after treatment with PEG/PEI nanocomplexes at 0.6 MPa as compared to 0.8 MPa. The combination of small diameter MBs and 0.6 MPa US also resulted in significantly greater gene expression when compared to concentration matched intramuscular injections, a control condition in which considerably more PEG/PEI nanocomplexes were present in tissue. This result suggests that, in addition to facilitating PEG/PEI nanocomplex delivery from the bloodstream to tissue, US enhances transfection via one or more secondary mechanisms, including increased cellular uptake and/or trafficking to the nucleus of PEG/PEI nanocomplexes. We conclude that PEG/PEI nanocomplexes may be used to markedly enhance the amplitude of US-MB-targeted skeletal muscle transfection and that activating small MBs with a moderate level (0.6 MPa) of acoustic pressure can further enhance these effects.

KW - Microbubbles

KW - Nanomedicine

KW - Non-viral gene delivery

KW - Polyethylenimine

KW - Skeletal muscle

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=84865341680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865341680&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2012.07.005

DO - 10.1016/j.jconrel.2012.07.005

M3 - Article

C2 - 22800583

AN - SCOPUS:84865341680

VL - 162

SP - 414

EP - 421

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -